[go: up one dir, main page]

MX2024002182A - Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). - Google Patents

Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).

Info

Publication number
MX2024002182A
MX2024002182A MX2024002182A MX2024002182A MX2024002182A MX 2024002182 A MX2024002182 A MX 2024002182A MX 2024002182 A MX2024002182 A MX 2024002182A MX 2024002182 A MX2024002182 A MX 2024002182A MX 2024002182 A MX2024002182 A MX 2024002182A
Authority
MX
Mexico
Prior art keywords
antibody
tgf
beta
antibody fragment
binding proteins
Prior art date
Application number
MX2024002182A
Other languages
English (en)
Inventor
Mark Throsby
Kruif Cornelis Adriaan De
Rinse Klooster
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2024002182A publication Critical patent/MX2024002182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo o fragmento de anticuerpo del mismo que específicamente se une al dominio extracelular de TGF-ßRII humano. La presente invención además se refiere a un vector que comprende un polinucleótido que codifica el anticuerpo o fragmento de anticuerpo de la invención, una célula aislada que produce el anticuerpo o fragmento de anticuerpo de la invención, y una composición farmacéutica que comprende el anticuerpo o fragmento de anticuerpo de la invención. El anticuerpo o fragmento de anticuerpo de la invención se puede usar para tratar cáncer.
MX2024002182A 2019-12-24 2022-06-23 Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). MX2024002182A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24

Publications (1)

Publication Number Publication Date
MX2024002182A true MX2024002182A (es) 2024-05-03

Family

ID=69700252

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022007919A MX2022007919A (es) 2019-12-24 2020-12-22 Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2024002182A MX2024002182A (es) 2019-12-24 2022-06-23 Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022007919A MX2022007919A (es) 2019-12-24 2020-12-22 Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).

Country Status (13)

Country Link
EP (2) EP4081306A1 (es)
JP (3) JP7633259B2 (es)
KR (2) KR20220117267A (es)
CN (3) CN115038497A (es)
AR (2) AR120914A1 (es)
AU (2) AU2020412201A1 (es)
BR (1) BR112022012522A2 (es)
CA (1) CA3165605A1 (es)
IL (2) IL294181A (es)
MX (2) MX2022007919A (es)
PH (1) PH12022551527A1 (es)
TW (2) TW202128747A (es)
WO (1) WO2021133167A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022389596A1 (en) * 2021-11-19 2024-05-30 Incyte Corporation Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
US20240218070A1 (en) 2022-12-20 2024-07-04 Merus N.V. FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-ßRII

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
SI2147594T1 (sl) 2008-06-27 2014-02-28 Merus B.V. Protitelo proizvajajoči ne-humani sesalci
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2012093125A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체

Also Published As

Publication number Publication date
PH12022551527A1 (en) 2024-01-29
EP4269433A2 (en) 2023-11-01
CN116199780A (zh) 2023-06-02
WO2021133167A1 (en) 2021-07-01
KR20230145542A (ko) 2023-10-17
JP2023076596A (ja) 2023-06-01
TW202417513A (zh) 2024-05-01
CN116375869A (zh) 2023-07-04
JP2025083342A (ja) 2025-05-30
AU2020412201A1 (en) 2022-07-14
KR20220117267A (ko) 2022-08-23
IL294181A (en) 2022-08-01
CA3165605A1 (en) 2021-07-01
MX2022007919A (es) 2022-07-27
BR112022012522A2 (pt) 2022-09-06
AU2023200779A1 (en) 2023-03-09
EP4081306A1 (en) 2022-11-02
AR120914A1 (es) 2022-03-30
AR130991A2 (es) 2025-02-05
CN115038497A (zh) 2022-09-09
JP2023508202A (ja) 2023-03-01
JP7633259B2 (ja) 2025-02-19
IL304317A (en) 2023-09-01
EP4269433A3 (en) 2024-05-22
TW202128747A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
NZ754051A (en) Novel antibodies and uses thereof
PH12020551997A1 (en) Psma binding agents and uses thereof
ZA202100676B (en) Anti-tigit antibody and uses thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EP4417263A3 (en) Cd3 binding antibodies
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
NZ774326A (en) Therapeutic antibodies and their uses
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
NZ759601A (en) Aggrecan binding immunoglobulins
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2024002182A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
PH12022550671A1 (en) Antigen binding proteins
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
WO2021012092A9 (en) A novel anti-pd-l1 antibody and use thereof